Reticulohistiocytic granuloma

Summary

Reticulohistiocytic granuloma (MONDO:0002984) is a disease. A subtype of histiocytosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	reticulohistiocytic granuloma
Mondo ID	MONDO:0002984
DOID	DOID:4394
NCIT	C3356
SNOMED CT	404162004
UMLS	C0035290
MedGen	48431
GARD	0012967
Is cancer (heuristic)	no

Also known as: reticulohistiocytic granuloma (morphologic abnormality) · solitary histiocytoma · solitary Reticulohistiocytoma · solitary reticulohistiocytoma · solitary reticulohistiocytosis

Disease family

This is a subtype of histiocytosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › lymphoid system disorder › lymphatic system disorder › histiocytosis › reticulohistiocytic granuloma

Related subtypes (4): malignant histiocytosis, non-Langerhans cell histiocytosis, Langerhans cell histiocytosis, ALK+ histiocytosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.